title: Targeted drugs in concert with chemo: opposites attract.
abstract: In this issue of Blood, Brown and colleagues show an impressive additional value when combining a tyrosine kinase inhibitor, that is, the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, with classic chemoimmunotherapy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma
authors.affiliation: KLINIKUM SCHWABING; UNIVERSITY OF COLOGNE.
authors.forename: Clemens-Martin
authors.initials: CM
authors.lastname: Wendtner
authors.affiliation: UNIVERSITY OF COLOGNE.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Fischer
mesh_terms: D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D011720:Pyrazoles; D011743:Pyrimidines; D011505:Protein-Tyrosine Kinases